Stem Cells – Failings and Deliveries
September 2009. Failings of stem cell applications raise questions on deliverables. How does venture capital respond? Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, as well as interests of venture capital, and evaluates the balance. Still full of insights many years after the first publication.Reading time: 4 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Novartis and Stem Cells
Mark Fishman, President Novartis Institutescomments on the company’s strategy and technology acquisitions in the field
Patenting Stem Cells – Behind the Front Stages
A legal approach solving problems with patentability
Thinking Further About Stem Cells - Viewed from Systems Biology
Leroy Hood, President Institute for Systems Biology, Seattle, Washington (US)
Sanofi: Triggering Regenerative Functions
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis